Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Health, Inc. (NASDAQ:JAGX) saw a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 35,700 shares, a decline of 96.3% from the February 28th total of 953,100 shares. Based on an average trading volume of 22,800 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.3% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Jaguar Health in a research report on Friday. They issued a “sell” rating for the company.

Jaguar Health Stock Performance

Shares of JAGX stock traded down $0.24 during mid-day trading on Friday, hitting $5.15. 13,704 shares of the company’s stock were exchanged, compared to its average volume of 28,006. The company has a debt-to-equity ratio of 1.65, a current ratio of 1.84 and a quick ratio of 1.36. Jaguar Health has a fifty-two week low of $4.90 and a fifty-two week high of $540.00. The stock has a 50-day simple moving average of $16.83 and a two-hundred day simple moving average of $23.42.

Institutional Trading of Jaguar Health

An institutional investor recently bought a new position in Jaguar Health stock. Virtu Financial LLC bought a new position in Jaguar Health, Inc. (NASDAQ:JAGX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 25,591 shares of the biotechnology company’s stock, valued at approximately $35,000. Virtu Financial LLC owned about 0.22% of Jaguar Health as of its most recent filing with the Securities and Exchange Commission (SEC). 12.04% of the stock is owned by institutional investors.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.